Literature DB >> 30381303

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Anton Hagenbeek1, Hans Mooij2, Josée Zijlstra3, Pieternella Lugtenburg4, Gustaaf van Imhoff5, Marcel Nijland5, Sanne Tonino2,6, Martin Hutchings7, Marjolein Spiering2, Roberto Liu2, Harm van Tinteren8, Marie José Kersten2,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30381303      PMCID： PMC6442967          DOI： 10.3324/haematol.2018.196899

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.

Authors:  Raynier Devillier; Diane Coso; Luca Castagna; Isabelle Brenot Rossi; Antonella Anastasia; Arturo Chiti; Vadim Ivanov; Jean Marc Schiano; Armando Santoro; Christian Chabannon; Monica Balzarotti; Didier Blaise; Reda Bouabdallah
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Authors:  Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

3.  Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.

Authors:  Anne-Sophie Michallet; Yann Guillermin; Benedicte Deau; Laure Lebras; Stephanie Harel; Sandy Amorin; Claire Reynes; Gilles Salles; Fabien Subtil; Pauline Brice
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

4.  U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

Authors:  R Angelo de Claro; Karen McGinn; Virginia Kwitkowski; Julie Bullock; Aakanksha Khandelwal; Bahru Habtemariam; Yanli Ouyang; Haleh Saber; Kyung Lee; Kallappa Koti; Mark Rothmann; Marjorie Shapiro; Francisco Borrego; Kathleen Clouse; Xiao Hong Chen; Janice Brown; Lara Akinsanya; Robert Kane; Edvardas Kaminskas; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2012-09-07       Impact factor: 12.531

5.  PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

Authors:  Alison J Moskowitz; Heiko Schöder; Joachim Yahalom; Susan J McCall; Stephanie Y Fox; John Gerecitano; Ravinder Grewal; Paul A Hamlin; Steven Horwitz; Rachel Kobos; Anita Kumar; Matthew Matasar; Ariela Noy; M Lia Palomba; Miguel-Angel Perales; Carol S Portlock; Craig Sauter; Neerav Shukla; Peter Steinherz; David Straus; Tanya Trippett; Anas Younes; Andrew Zelenetz; Craig H Moskowitz
Journal:  Lancet Oncol       Date:  2015-02-13       Impact factor: 41.316

6.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Authors:  Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

7.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

8.  Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Authors:  A Josting; C Rudolph; M Reiser; M Mapara; M Sieber; H H Kirchner; B Dörken; D K Hossfeld; V Diehl; A Engert
Journal:  Ann Oncol       Date:  2002-10       Impact factor: 32.976

9.  Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Authors:  Robert Chen; Joycelynne M Palmer; Peter Martin; Nicole Tsai; Young Kim; Bihong T Chen; Leslie Popplewell; Tanya Siddiqi; Sandra H Thomas; Michelle Mott; Firoozeh Sahebi; Saro Armenian; John Leonard; Auayporn Nademanee; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-26       Impact factor: 5.742

Review 10.  Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.

Authors:  Hugo J A Adams; Thomas C Kwee
Journal:  Ann Hematol       Date:  2016-03-02       Impact factor: 3.673
  10 in total
  11 in total

1.  Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.

Authors:  Armando Santoro; Rita Mazza; Alessandro Pulsoni; Alessandro Re; Maurizio Bonfichi; Vittorio Ruggero Zilioli; Manuela Zanni; Francesco Merli; Antonella Anastasia; Stefano Luminari; Giorgia Annechini; Manuel Gotti; Annalisa Peli; Anna Marina Liberati; Nicola Di Renzo; Luca Castagna; Laura Giordano; Francesca Ricci; Carmelo Carlo-Stella
Journal:  Blood Adv       Date:  2020-01-14

Review 2.  Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.

Authors:  Shinichi Makita; Dai Maruyama; Kensei Tobinai
Journal:  Onco Targets Ther       Date:  2020-06-23       Impact factor: 4.147

3.  Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma.

Authors:  Elda-Georgina Chavez-Cortez; Gustavo Vargas Felix; Edgar Rangel López; Julio Sotelo; Carlos Martínez-Canseco; Verónica Pérez-de la Cruz; Benjamin Pineda
Journal:  J Oncol       Date:  2019-06-02       Impact factor: 4.375

Review 4.  Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.

Authors:  Kenichi Ishizawa; Tomoko Yanai
Journal:  Adv Ther       Date:  2019-08-07       Impact factor: 3.845

Review 5.  The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma.

Authors:  Catherine Lai; Adrese Michael Kandahari; Chaitra Ujjani
Journal:  Blood Lymphat Cancer       Date:  2019-12-09

6.  Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.

Authors:  Marie José Kersten; Julia Driessen; Josée M Zijlstra; Wouter J Plattel; Franck Morschhauser; Pieternella J Lugtenburg; Pauline Brice; Martin Hutchings; Thomas Gastinne; Roberto Liu; Coreline N Burggraaff; Marcel Nijland; Sanne H Tonino; Anne I J Arens; Roelf Valkema; Harm van Tinteren; Marta Lopez-Yurda; Arjan Diepstra; Daphne De Jong; Anton Hagenbeek
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

7.  Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.

Authors:  Fulvio Massaro; Vincenzo Pavone; Piero Maria Stefani; Barbara Botto; Alessandro Pulsoni; Caterina Patti; Maria Cantonetti; Andrea Visentin; Potito Rosario Scalzulli; Andrea Rossi; Sara Galimberti; Michele Cimminiello; Guido Gini; Maurizio Musso; Marco Sorio; Annalisa Arcari; Vittorio Ruggero Zilioli; Mario Luppi; Donato Mannina; Alberto Fabbri; Giuseppe Pietrantuono; Ombretta Annibali; Agostino Tafuri; Eleonora Prete; Antonino Mulè; Elisa Barbolini; Luigi Marcheselli; Stefano Luminari; Francesco Merli
Journal:  Hematol Oncol       Date:  2021-11-01       Impact factor: 4.850

Review 8.  Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.

Authors:  Theodoros P Vassilakopoulos; John V Asimakopoulos; Kostas Konstantopoulos; Maria K Angelopoulou
Journal:  Ther Adv Hematol       Date:  2020-02-16

9.  First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Authors:  A Broccoli; L Argnani; B Botto; P Corradini; A Pinto; A Re; U Vitolo; S Fanti; V Stefoni; P L Zinzani
Journal:  Blood Cancer J       Date:  2019-12-11       Impact factor: 11.037

Review 10.  Antibody-Drug Conjugates: The Last Decade.

Authors:  Nicolas Joubert; Alain Beck; Charles Dumontet; Caroline Denevault-Sabourin
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.